{"name":"ADARx Pharmaceuticals, Inc.","slug":"adarx-pharmaceuticals-inc","ticker":"","exchange":"","domain":"adarx.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ADX-850","genericName":"ADX-850","slug":"adx-850","indication":"Other","status":"phase_1"},{"name":"ADX-038 Dose Level 2","genericName":"ADX-038 Dose Level 2","slug":"adx-038-dose-level-2","indication":"Other","status":"phase_2"},{"name":"ADX-324","genericName":"ADX-324","slug":"adx-324","indication":"Duchenne muscular dystrophy (DMD)","status":"phase_3"},{"name":"ADX-626","genericName":"ADX-626","slug":"adx-626","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ADX-038","genericName":"ADX-038","slug":"adx-038","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"ADX-324 Dose Level 1","genericName":"ADX-324 Dose Level 1","slug":"adx-324-dose-level-1","indication":"Autoimmune or inflammatory disease (specific indication not publicly detailed for Phase 3)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"ADX-038 Dose Level 1","genericName":"ADX-038 Dose Level 1","slug":"adx-038-dose-level-1","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"ADX-324 Dose Level 2","genericName":"ADX-324 Dose Level 2","slug":"adx-324-dose-level-2","indication":"Advanced solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"}]}],"pipeline":[{"name":"ADX-850","genericName":"ADX-850","slug":"adx-850","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADX-038","genericName":"ADX-038","slug":"adx-038","phase":"phase_2","mechanism":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ADX-038 Dose Level 1","genericName":"ADX-038 Dose Level 1","slug":"adx-038-dose-level-1","phase":"phase_2","mechanism":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"ADX-038 Dose Level 2","genericName":"ADX-038 Dose Level 2","slug":"adx-038-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADX-324","genericName":"ADX-324","slug":"adx-324","phase":"phase_3","mechanism":"ADX-324 is an ADAR enzyme activator that enhances adenosine-to-inosine RNA editing to modulate gene expression and protein function.","indications":["Duchenne muscular dystrophy (DMD)"],"catalyst":""},{"name":"ADX-324 Dose Level 1","genericName":"ADX-324 Dose Level 1","slug":"adx-324-dose-level-1","phase":"phase_3","mechanism":"ADX-324 is an ADAR inhibitor that reduces adenosine-to-inosine RNA editing to modulate immune and inflammatory responses.","indications":["Autoimmune or inflammatory disease (specific indication not publicly detailed for Phase 3)"],"catalyst":""},{"name":"ADX-324 Dose Level 2","genericName":"ADX-324 Dose Level 2","slug":"adx-324-dose-level-2","phase":"phase_3","mechanism":"ADX-324 is an ADAR1 inhibitor that modulates RNA editing to enhance innate immune responses against cancer.","indications":["Advanced solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"ADX-626","genericName":"ADX-626","slug":"adx-626","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOQ09TNHJSTzFYZDVNZmlxV0IxWk5qMkRKOENlNFFXX3dOaWg2Y2FURExsOEFSbHcyRzV3SEhEMzcwT05LNWtXTEM2elpkb2xhXzNvWkpnTENnRDd6bzBGYzZxYzlxSmcydnZFS2VXczlqRG43RmRzdXpKQ0E5NUxBOFFKaWJTZzktRFZrQk1GZ1NBaE1W?oc=5","date":"2026-03-28","type":"pipeline","source":"The Pharma Letter","summary":"ADARx Pharmaceuticals expands leadership team - The Pharma Letter","headline":"ADARx Pharmaceuticals expands leadership team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNaktHUG91UzR4LVdWc2dyeEV1UDJQaGMzSlZsMFJmVVZwaDUxbWNlQkJ5ek0xZkQxbC1sWW4tcVR3U2s1SHAzYWJKdzRLZUxXY0ZIRGkwcld4WkdlbXEyYlBGOHB6bVgwVDdIcWEyNHF5c09USUN6TlMteVdZUXlCTnRLWml6dm9ZckU0eHJXbWZreEctdHp1RlJVaFo3QlVkLVJYUG9BTXJ4TURZV3c?oc=5","date":"2026-02-06","type":"pipeline","source":"The Pharma Letter","summary":"ADARx Pharmaceuticals names Donald Fong as chief medical officer - The Pharma Letter","headline":"ADARx Pharmaceuticals names Donald Fong as chief medical officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWFhLYlRKOHMwdzNxbkhOMFF5bXlFbmM4eHFMc0VXalhraXIwZmRKT3NkR0NwSWRtS0xCY3dzMjFDamgwSDd4UHl1YUp3LTJPeGhTRXFKOXhRb0U2Y1FFOEtZa0g5Nm51WHlwbW8yeGNxSFUtQW5yTVJPUTNueUV3Vk9WeWVtaTFrQjlMXzVwWWxaRGNOYmtEcmRiWQ?oc=5","date":"2026-02-05","type":"pipeline","source":"Contract Pharma","summary":"ADARx Pharmaceuticals Appoints Donald Fong as CMO - Contract Pharma","headline":"ADARx Pharmaceuticals Appoints Donald Fong as CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxObUEzWEliN2FGS1VhcEF4Uy1PcERveWljd2ZxM1ZaWVZicEZiVmw4MzVEaEo1MmJXdktCVTJpVnRDVy03aU9ITEpBVnJSQ0hxR25DMEplSGpwV1BoQ1I1SFlYcmxETkNqQW1odGVubGFIc1ZMMFIxblZVenBtcTZlMXpxdXpmZWJJYjJwZkFJU2VSektlejlQVzJMVWkxOFNsU1NSYVhwcjd1bzZz?oc=5","date":"2025-08-12","type":"pipeline","source":"BioSpace","summary":"U.S. Antiviral Drugs Market Size to Surpass USD 21.94 Billion By 2034 - BioSpace","headline":"U.S. Antiviral Drugs Market Size to Surpass USD 21.94 Billion By 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQb3JEbHdDUWxDWDNSTUpHVHMteWJqTHRWR3dWZTgwUWpGTHlYRUVhTVhnamFtMzF5eG02ckt3NWxpZ3FxS1hXaHduR2lGU3djZ0dJZkhFSTBWclhPSHNKNEdkSTJWdnczNmUzWDVwWmYxYWlPdExKOTJxZkxoaEE2NGU0UWlhRkdkMzl3UEtPNA?oc=5","date":"2025-05-15","type":"pipeline","source":"BioPharma Dive","summary":"AbbVie stakes $335M on a startup’s RNAi drugs - BioPharma Dive","headline":"AbbVie stakes $335M on a startup’s RNAi drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOLTROaHloM3Z5WFo1Q0VkM0d2cUxkMGFzWnZYYTVKdWd0el9UNlRhYmZ1dmxTWWtjU2M0bGFhRnFaTjF1WTliQ2JIQU54OTBNdm1Va2NvR05Lc2pqNGN2UEsyOHAyRXBabGVHcjM5dy1sOUhHMm9semFnbkFIdTNwMlcyQjViQVdtN2p5dEtIdi1rdzRaVDFkbHJQUmp2Zw?oc=5","date":"2025-05-15","type":"deal","source":"Contract Pharma","summary":"AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics - Contract Pharma","headline":"AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOR2t3X2NCZzJpU0lVRVc5X1dJZklJXy16OWdwU202SHFXdWh2bUFyaTl1WjN4SXJVSzRITm4yZGhTZ3pmTjFtZFN2T3RRWnROcmJsMWhkWnA4LXBFVkR1V1BzSTlCLUM3bm1sNFhUVVBmbnQxU2k4Wmc5Ni1iQkJZOHF2eS04UklseUFST1FtOFNoeU1wUDlMNEEyYjdJS1MxQXFLWEdQbzFtMS01U1YtUkJIb09tTDZ5YnhDNXhPVEZCSEh6TmwtUEU2am92RndqdjBiTTlidlMyblZCYnYtWWk1dnNDRURsekNIeXowdHNYU2QzMF8yb2dwZWh2YURMQmFVSmt3WlpGWWdsMWhLRXRDby1pcFEtV01UZV9hLTluTktMYzJuZmJmLWhJWHZPblo0TWJvd3JvOHVzUEE?oc=5","date":"2025-05-14","type":"deal","source":"PR Newswire","summary":"AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas - PR Newswire","headline":"AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNTUU0eS1JVkJTT2R2NS03SzZBTGVZbnJiclozbllOSlBPcXNRc3lwaTVEQmFpZHE0Ym5CUFBHQTlDaENEeDZtTTlkbWRrbDBuemRWUlI3X3BpRXpmZ2Y5YzJGQXJsR1ZCOUpRVDJBQUZvajYtRERSMlQxcDFLRkIxZnFsNUVBTk1kRjNwMkEwQlJYLUdQemJHZkVZUGxRdw?oc=5","date":"2025-05-14","type":"pipeline","source":"Fierce Biotech","summary":"AbbVie pays ADARx $335M cash for next-gen siRNA options - Fierce Biotech","headline":"AbbVie pays ADARx $335M cash for next-gen siRNA options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNbEhrU3hIODFTY2JhbTNEeUpMWnZSd2VfRU1Qb1NSc21RTFFETS1ZajZqYW9YLUtOa3VlUkRGZktrd3l4NEN6bzdHSEtDaTNwMEIxY3VYMkV0QmxrVGJIYWh3YmdsYlQxRDlkMHV1SXB3NHJVVHNDM2VQMUNJYTA2MmNLUllic3JKY2ljRFROQ1ptclBjN25NSm9n?oc=5","date":"2025-05-14","type":"deal","source":"BioSpace","summary":"AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal - BioSpace","headline":"AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBKbUliRGdMYXVNUWpDbnhwdndRaFBoR0ZKNmlET0JjeGpVN01PVUNnNW83Y3RZZzlFdWVXRl8zekVwcGE2clFFQTc1YjBSc3FyYWFn?oc=5","date":"2025-05-14","type":"pipeline","source":"FirstWord Pharma","summary":"AbbVie bets $335M upfront for ADARx's gene-silencing tech - FirstWord Pharma","headline":"AbbVie bets $335M upfront for ADARx's gene-silencing tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWUFMaXhzc2dyX0VRU3ZKRXpHUW12RXdSNjBYcnJ6cXdQQnpqR0hHN3lrSDJTdmk1R1RXRGxsM1VoNXBmeUsxXzJIOG9KMzJ2RGpWZWxQWWN5XzdBV215aTYzbU5aaHNCdHlXWVFnaGo1QmQ3SnhBaHd0YnRzX0pUb25fX1lTWkhyS3U3OXpEb3FWWUtlNm5NWjJQTnVTVGhQUWxzR25xN0NEVnpZTElMM1IzSDBqWXZtdjdBRmlPNFI?oc=5","date":"2023-08-09","type":"pipeline","source":"Bain Capital","summary":"ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing - Bain Capital","headline":"ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Fina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQclpwNS0tQ2RiVlhfcldMZmloZHFRVnRTT3F4SFFzRTdzeG1QVUdzSE1iVnpvcGlWNjlVclJPMk5pNlZnRk9DWVZiLXFYUEFIOVF1T0FWSUR2d0ZLbmlpbHdQeXNxSEo0WWxQVEl3YjhLQlE1NmxLX3ozb2VkSElra3FRSTZsY1pzeE55WHdfRDc1dV81Z195Zll4RTNEN1VlQnB1RGI5aWJ3UHJDTkhYRlVaWTZySGhueWVBRVY0eU9xcVhfTy0xLXBmRzZHdw?oc=5","date":"2023-01-20","type":"pipeline","source":"businesswire.com","summary":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - businesswire.com","headline":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_1":2,"phase_2":3,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}